No Data
Market Still Lacking Some Conviction On Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456)
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The wholly-owned subsidiary has obtained the recognition as a high-tech enterprise.
On December 26, Gelonghui reported that Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Ribo (Hangzhou) Medical Technology Co., Ltd. (referred to as "Ribo Hangzhou"), has passed the high-tech enterprise identification as per the recent announcement by the National High-Tech Enterprise Identification Management Work Leading Group Office regarding the filing of high-tech enterprises recognized by Institutions in Zhejiang Province for 2024. The certificate number is GR202433008949, issued on December 6, 2024, and is valid for three years.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The controlling subsidiary plans to be selected for the tenth batch of national Pharmaceutical centralized procurement.
Gelonghui reported on December 13 that Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its holding subsidiary, Zhejiang Jiuzhou Biomedical Co., Ltd., participated in the bidding for the tenth batch of national centralized procurement organized by the National Joint Procurement Office (referred to as "Joint Procurement Office"). The company's product, Sitagliptin and Metformin Tablets (II), is expected to be selected in this centralized procurement. In March 2024, the company received the Drug Registration Certificate for Sitagliptin and Metformin Tablets (II) issued by the National Medical Products Administration. As of now, the sales revenue of this product is 0.8029 million yuan, expected to account for a portion of the company's 2024 revenue.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Plans to use the remaining raised funds of 48.7058 million yuan (including interest) for the permanent replenishment of working capital.
On December 13, according to Gelonghui, Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that, as the non-public issuance of Stocks fundraising project "Ruibo (Hangzhou) Pharmaceutical Technology Co., Ltd. Research and Development Center Project" has reached the intended operational state for the year 2020, the company intends to conclude the aforementioned fundraising project and use the remaining raised funds of 48.7058 million yuan (including interest) to permanently supplement working capital, with the specific amount for permanent supplementation based on the actual balance of the raised funds special account at the time of transfer.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Subsidiary recognized as a high-tech enterprise.
On December 13, Gelonghui reported that Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that, according to the recent notice from the Office of the Leading Group for the Recognition of National High-tech Enterprises regarding the second batch of high-tech enterprises for recognition and filing in Jiangsu Province for 2024, the wholly-owned subsidiary of Zhejiang Jiuzhou Pharmaceutical Co., Ltd., Reibo (Suzhou) Pharmaceutical Co., Ltd., has passed the high-tech enterprise recognition, with certificate number GR202432005007, issued on November 19, 2024, and valid for three years. This is the first recognition of Reibo Suzhou as a high-tech enterprise.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Currently not involved in AI applications.
GlobeNewswire reported on December 11 that Zhejiang Jiuzhou Pharmaceutical (603456.SH) stated on the investor interaction platform that the company currently does not involve applications in AI.
Those Who Invested in Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Five Years Ago Are up 174%
